PureTech Health (LON:PRTC) Reaches New 12-Month Low – Should You Sell?

PureTech Health plc (LON:PRTC)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 138 ($1.71) and last traded at GBX 143 ($1.77), with a volume of 1221521 shares changing hands. The stock had previously closed at GBX 140 ($1.73).

Analysts Set New Price Targets

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 455 ($5.62) target price on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Stock Up 2.1 %

The company has a debt-to-equity ratio of 47.27, a quick ratio of 2.51 and a current ratio of 3.68. The firm has a market capitalization of £342.37 million, a P/E ratio of -621.74 and a beta of 1.02. The stock has a 50 day moving average of GBX 161.30 and a 200-day moving average of GBX 162.91.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.